Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain

Andrew S. Gdowski, Amalendu Ranjan, Marjana R. Sarker, Jamboor K. Vishwanatha

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aim: The aim of this study was to develop a novel cabazitaxel bone targeted nanoparticle (NP) system for improved drug delivery to the bone microenvironment. Materials & methods: Nanoparticles were developed using poly(D,L-lactic-co-glycolic acid) and cabazitaxel as the core with amino-bisphosphonate surface conjugation. Optimization of nanoparticle physiochemical properties, in vitro evaluation in prostate cancer cell lines and in vivo testing in an intraosseous model of metastatic prostate cancer was performed. Results: This bone targeted cabazitaxel nanocarrier system showed significant reduction in tumor burden, while at the same time maintaining bone structure integrity and reducing pain in the mouse tumor limb. Conclusion: This bone microenvironment targeted nanoparticle system and clinically relevant approach of evaluation represents a promising advancement for treating bone metastatic cancer.

Original languageEnglish
Pages (from-to)2083-2095
Number of pages13
JournalNanomedicine
Volume12
Issue number17
DOIs
StatePublished - Sep 2017

Fingerprint

lesion
Nanoparticles
pain
bone
cancer
Prostatic Neoplasms
Bone
Bone and Bones
Pain
evaluation
tumor
integrity
Tumors
Bone Neoplasms
drug
Diphosphonates
Drug Delivery Systems
Tumor Burden
Drug delivery
Extremities

Keywords

  • bone metastasis
  • cabazitaxel
  • polymeric nanoparticle
  • prostate cancer
  • targeted therapeutic

Cite this

@article{665f1008f75d48ff9310c27d76b981e7,
title = "Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain",
abstract = "Aim: The aim of this study was to develop a novel cabazitaxel bone targeted nanoparticle (NP) system for improved drug delivery to the bone microenvironment. Materials & methods: Nanoparticles were developed using poly(D,L-lactic-co-glycolic acid) and cabazitaxel as the core with amino-bisphosphonate surface conjugation. Optimization of nanoparticle physiochemical properties, in vitro evaluation in prostate cancer cell lines and in vivo testing in an intraosseous model of metastatic prostate cancer was performed. Results: This bone targeted cabazitaxel nanocarrier system showed significant reduction in tumor burden, while at the same time maintaining bone structure integrity and reducing pain in the mouse tumor limb. Conclusion: This bone microenvironment targeted nanoparticle system and clinically relevant approach of evaluation represents a promising advancement for treating bone metastatic cancer.",
keywords = "bone metastasis, cabazitaxel, polymeric nanoparticle, prostate cancer, targeted therapeutic",
author = "Gdowski, {Andrew S.} and Amalendu Ranjan and Sarker, {Marjana R.} and Vishwanatha, {Jamboor K.}",
year = "2017",
month = "9",
doi = "10.2217/nnm-2017-0190",
language = "English",
volume = "12",
pages = "2083--2095",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "17",

}

Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. / Gdowski, Andrew S.; Ranjan, Amalendu; Sarker, Marjana R.; Vishwanatha, Jamboor K.

In: Nanomedicine, Vol. 12, No. 17, 09.2017, p. 2083-2095.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain

AU - Gdowski, Andrew S.

AU - Ranjan, Amalendu

AU - Sarker, Marjana R.

AU - Vishwanatha, Jamboor K.

PY - 2017/9

Y1 - 2017/9

N2 - Aim: The aim of this study was to develop a novel cabazitaxel bone targeted nanoparticle (NP) system for improved drug delivery to the bone microenvironment. Materials & methods: Nanoparticles were developed using poly(D,L-lactic-co-glycolic acid) and cabazitaxel as the core with amino-bisphosphonate surface conjugation. Optimization of nanoparticle physiochemical properties, in vitro evaluation in prostate cancer cell lines and in vivo testing in an intraosseous model of metastatic prostate cancer was performed. Results: This bone targeted cabazitaxel nanocarrier system showed significant reduction in tumor burden, while at the same time maintaining bone structure integrity and reducing pain in the mouse tumor limb. Conclusion: This bone microenvironment targeted nanoparticle system and clinically relevant approach of evaluation represents a promising advancement for treating bone metastatic cancer.

AB - Aim: The aim of this study was to develop a novel cabazitaxel bone targeted nanoparticle (NP) system for improved drug delivery to the bone microenvironment. Materials & methods: Nanoparticles were developed using poly(D,L-lactic-co-glycolic acid) and cabazitaxel as the core with amino-bisphosphonate surface conjugation. Optimization of nanoparticle physiochemical properties, in vitro evaluation in prostate cancer cell lines and in vivo testing in an intraosseous model of metastatic prostate cancer was performed. Results: This bone targeted cabazitaxel nanocarrier system showed significant reduction in tumor burden, while at the same time maintaining bone structure integrity and reducing pain in the mouse tumor limb. Conclusion: This bone microenvironment targeted nanoparticle system and clinically relevant approach of evaluation represents a promising advancement for treating bone metastatic cancer.

KW - bone metastasis

KW - cabazitaxel

KW - polymeric nanoparticle

KW - prostate cancer

KW - targeted therapeutic

UR - http://www.scopus.com/inward/record.url?scp=85027682794&partnerID=8YFLogxK

U2 - 10.2217/nnm-2017-0190

DO - 10.2217/nnm-2017-0190

M3 - Article

C2 - 28805551

AN - SCOPUS:85027682794

VL - 12

SP - 2083

EP - 2095

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 17

ER -